<DOC>
	<DOCNO>NCT02020616</DOCNO>
	<brief_summary>The purpose study investigate safety effectiveness study drug know LY3053102 participant Type 2 diabetes mellitus . The study drug give different dos injection skin . The study expect last 6 month participant . Participants may remain stable-dose metformin prescribe personal physician .</brief_summary>
	<brief_title>A Study Safety Effectiveness LY3053102 Participants With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Inclusion Criteria Participants type 2 diabetes mellitus least 6 month enter trial base disease diagnostic criterion ( World Health Organization [ WHO ] ) classification manage diet exercise alone stable dose metformin least 1000 mg/day least 60 day screen metformin eligible second oral antihyperglycemic medication 60day washout second oral antihyperglycemic medication Women childbearing potential due surgical sterilization ( hysterectomy bilateral oophorectomy tubal ligation ) menopause Have hemoglobin A1c value ≥7.0 % ≤10.5 % , diet exercise diet , exercise , metformin ( stable dose least 1000 mg/day least 60 day ) , hemoglobin A1c value ≥7.0 % ≤9.5 % , appropriate diet exercise regimen , stable dose metformin willing discontinue second oral antihyperglycemic medication Have body mass index ≥23 ≤45 kilogram per square meter ( kg/m^2 ) Exclusion Criteria Have use insulin diabetic control 6 consecutive day within 1 year prior screen Have use thiazolidinediones within 3 month , drug treatment hyperglycemia ( except metformin ) within 2 month , prior first week study Have hepatitis B and/or positive hepatitis B surface antigen . hepatitis C human immunodeficiency virus ( HIV ) and/or positive HIV antibody Have know suspected cardiac autonomic neuropathy ( example , rest tachycardia orthostatic hypotension ) , base clinical sign , symptom , appropriate diagnostic testing Have cardiac disease functional status New York Heart Association Class II , III , IV last 6 month follow : history myocardial infarction , unstable angina , coronary artery bypass graft , percutaneous coronary intervention ( diagnostic angiogram permit ) , transient ischemic attack , cerebrovascular accident ( example , stroke ) Have poorly control hypertension , malignant hypertension , renal artery stenosis , and/or evidence labile blood pressure include symptomatic postural hypotension . Doses antihypertensive medication must stable 30 day prior first week study Have obvious clinical sign symptom liver disease , acute chronic hepatitis , alanine transaminase aspartate aminotransferase level &gt; 2 time upper limit reference range Have evidence hypothyroidism hyperthyroidism base clinical evaluation and/or abnormal thyroidstimulating hormone , opinion investigator , would pose risk participant safety . Participants stable dose thyroid replacement therapy may eligible meet criterion Have clinically significant peripheral vascular disease , clinical evidence active diabetic proliferative retinopathy , ( know significant autonomic neuropathy ) evidence urinary retention , orthostatic hypotension , diabetic diarrhea gastroparesis Have active untreated malignancy remission clinically significant malignancy ( basal squamous cell skin cancer , situ carcinoma cervix , situ prostate cancer ) less 5 year Have impair renal function Have fast triglyceride &gt; 500 milligram per deciliter ( mg/dL ) screening Have experience ketoacidotic episode require hospitalization last 6 month Have electrocardiogram ( ECG ) consider indicative cardiac disease Have personal family history long QT syndrome , family history sudden death firstdegree relative age 40 , personal history unexplained syncope within last year . Use prescription overthecounter medication know prolong QT QTc interval Have history bone disease ( include osteoporosis unhealed fracture ) , evidence osteoporosis ( femoral neck lumbar spine Tscore &lt; 2.5 ) determine dual Xray absorptometry ( DXA ) scan screening , evidence osteopenia ( Tscore 1.0 2.5 femoral neck lumbar spine ) high risk fracture base risk factor current active treatment periodontal disease</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>